31 results about "Venous malformation" patented technology

Methods and apparatus for treating or preventing endoleaks after an endovascular graft (e.g., a stent, tubular graft, stent-graft, coated stent, covered stent, intravascular flow modifier or other endovascular implant that affects, limits or prevents blood flow into a vascular defect such as an aneurysm, arterio-venous fistula, arterio-venous malformation, vessel wall perforation, etc.) has been implanted in the vasculature of a human or veterinary patient. An expansile polymeric material, such as a swellable polymer (e.g., a hydrogel), a flexible or elastomeric polymer foam (e.g. silicone, polyurethane, etc.) or a carrier member (e.g, a coil, filament, wire, etc) that carries a quantity of such expansile polymer is delivered into a perigraft space (i.e., space between the endovascular graft and the surrounding blood vessel wall) such that the polymeric material expands in situ to substantially fill the perigraft space or a portion thereof. The expansile polymeric material is delivered into he perigraft space through a catheter and/or cannula that is placed prior to, during or after the implantation of the endovascular graft. The invention includes an injector apparatus that is useable to deliver the expansile polymeric material through the wall of a previously implanted graft. After delivery into the perigraft space, the expanded polymeric material expands so as to fill all or an intended portion of the perigraft space in a manner that substantially prevents additional blood from leaking or flowing into such perigraft space. One type of blood-absorbing, porous, expansile polymeric material useable in this invention is a super-expansile hydrogel.

The present invention comprises compositions and methods for forming an endovascular occlusion to treat conditions such as aneurysms, arterio-venous malformations, excessive blood supply to tumors, massive vascular hemorrhaging, and other conditions which require an embolization to alleviate the condition. Embodiments of the present invention comprise compositions and methods that use calcium alginate, without or without endovascular coils or similar devices, to form occlusions at a site within the mammalian body targeted for occlusion.

Systems and methods treat superficial venous malformations, such as spider veins. The systems and methods distribute a reactive agent, e.g., a light-reactive agent such as talaporfin sodium or verteporfin, at or near an inner wall of a vein. The systems and methods activate the reactive agent by applying energy, e.g. non-thermal light energy at a wavelength that activates the reactive agent to cause localized injury to the inner wall of the vein.

The invention relates to an implant (1) for blood vessels, in particular for influencing the blood flow in the area of arteriovenous defects, with a wall made up of individual filaments (2), which are brought together to form a substantially tubular mesh that extends in an axial direction from a proximal end to a distal end, wherein the individual filaments (2) cross one another and form intersections (3) with one another, wherein the implant (1) is deformable in such a way that, in an insertion catheter, it adopts a shape with a reduced diameter and, at the site of implantation, expands to adapt to the diameter of the blood vessel, wherein the filament ends are in each case brought together at least in pairs at the proximal and/or distal end of the mesh and are permanently interconnected, wherein the interconnected filament ends are shaped to be atraumatic,; and wherein the filaments (2) crossing one another at the intersections (3) lying distally from the filament ends are connected directly or indirectly to one another at the proximal end (10) of the implant (1). This ensures that the implant (1), after release, also expands at the proximal end as far as the vessel walls, and the filament ends do not protrude into the vessel lumen.

An implant for blood vessels, in particular to influence the flow of blood in the area of arteriovenous malformations. The implant has a wall comprising individual filaments combined so as to form a circular braiding, the circular braiding being positioned in elongated form and with a reduced diameter in an insertion catheter and expanding at the placement site thus adapting to the vessel diameter and increasing its braiding density.

Systems and methods treat superficial venous malformations, such as spider veins. The systems and methods distribute a light-reactive agent, e.g., verteporfin, at or near an inner wall of a vein. The systems and methods activate the light-reactive agent by applying non-thermal light energy at a wavelength that activates the light-reactive agent to cause localize injury to the inner wall of the vein.

The invention discloses a developing foam hardening agent for treating venous malformations. The developing foam hardening agent comprises two effective ingredients, namely, polycinnamyl alcohol and ultravist, in a volume ratio of 2:1. A preparation method of the developing foam hardening agent specifically comprises the following steps of: extracting the polycinnamyl alcohol and the ultravist using by using a syringe according to a formula ratio, shaking and mixing up uniformly, extracting sterile air by using another syringe, connecting the two syringes by using a medicinal three-way valve, and injecting front and back for multiple times according to a Tessari method so as to mix the polycinnamyl alcohol and the ultravist into uniform and stable foams, wherein the volume ratio of the polycinnamyl alcohol to the sterile air is 1:4. According to the preparation method, a hardening agent, namely, a polycinnamyl alcohol injection, and a contrast agent, namely, the ultravist, are mixed up according to appropriate ratio and prepared into a foam hardening agent, the foam hardening agent is more stable when being compared with a hardening agent which is prepared from polycinnamyl alcohol and air merely, and the foam hardening agent is injected into venous malformation lesion in a partial puncture mode under the mediation of DSA (Digital Subtraction Angiography), so that precision, visualization and idealization in a curative effect are achieved.

The invention discloses a novel application of lauromacrogol in preparing a medicament for treating sublingual gland cyst, belonging to novel applications of old medicaments. When a patient with both mouth floor venous malformation and the sublingual gland cyst is treated, the lauromacrogol is locally injected for treating the venous malformation, and the sublingual gland cyst is accidently found to be also cured, so that lauromacrogol injection therapy is carried out on multiple patients simply with the sublingual gland cyst immediately, and the patients are observed and found to be all cured. Therefore, the medicament for treating the sublingual gland cyst can be prepared from the lauromacrogol as a raw material. While, with adoption of the lauromacrogol for therapy, injection time is small, curative effect is good, and adverse reaction does not exist.

The invention relates to a human brain arteriovenous malformation biomechanics model and an in vitro establishing method thereof. The system comprises a power pump, a gas replacement device, a pressure sensor, a malformation vascular model, a normal bran microvascular model and a liquid storage bottle which are connected in sequence and form a blood feeding artery model circulation loop, wherein the malformation vascular model and the normal bran microvascular model are arranged in parallel. The invention provides the human brain arteriovenous malformation biomechanics model and the in vitro establishing method thereof, which are used for developing research on brain blood vessel fluid dynamics, cytobiology and a vessel malformation mechanism.

The invention discloses a kit for mutation detection of a pathogenic gene POU3F4 of inner-ear malformation/incomplete separation type-III cochlear malformation. The kit comprises a reagent for extracting DNA from a sample to be detected, a PCR reaction reagent for amplifying the DNA of the sample, and a reagent for sequencing a PCR amplification product. The PCR reaction reagent for amplifying theDNA of the sample comprises a PCR primer. The kit is used for detecting whether or not mutation of the POU3F4 gene c.255_297del43 happens to a patient so as to diagnose the cause of the occurrence ofinner-ear malformation/incomplete separation type-III cochlear malformation. The kit is beneficial to clinical implementation of POU3F4 mutation screening work on patients suffering from inner-ear malformation/incomplete separation type-III cochlear malformation and provides a basis for the diagnosis of the patients suffering from inner-ear malformation/incomplete separation type-III cochlear malformation.

The invention provides a non-invasive detection method for venous malformation and related syndromes. The non-invasive detection method at least comprises the following steps: providing sequencing data of venous malformation related genes in free DNA (Deoxyribose Nucleic Acid) of plasma of a detected object, wherein the vein malformation related gene is selected from one or more of TEK, PIK3CA, AKT1, MTOR and PTEN; and comparing the sequencing data with a reference sequence to obtain mutations related to vein malformation and related syndromes. Free DNA liquid biopsy is used for replacing tissue biopsy, a series of complications caused by tissue biopsy are avoided, non-invasion is achieved, operation is safe, materials are convenient to take, side effects are small, and materials can be taken repeatedly. The method can be widely applied to mutation detection of people suffering from vein malformation and related syndromes, a perfect vein malformation biological sample library is constructed, and original data support is provided for clinical and biological research.

The invention belongs to the technical field of laboratory animals, and relates to a cell mixture and a preparation method and application thereof, especially, to an application of a mixture of adipose-derived stem cells (ADSCs) and immortalized human umbilical vein endothelial cells to preparation of a preparation for interfering and establishing a vascular malformation animal model. The mixture of adipose-derived stem cells (ADSCs) and immortalized human umbilical vein endothelial cells is used for interfering and establishing a vascular malformation animal model. The result shows that the vascular malformation animal model can be obtained at low cost, in a short period, and with high efficiency; and the established vascular malformation animal model of a nude mouse is obviously visible in vascular malformation and makes a significant practical sense in researching pathogenesis of vascular malformation and screening of clinical medicine treatment.

The invention provides a complexing agent for treating vascular malformation and a preparation method and application thereof, and belongs to the technical field of medicines. The complexing agent is composed of a fibrous protein adhesive and a pingyangmycin complexing agent, and the pingyangmycin complexing agent comprises pingyangmycin freeze-dried powder, sapponin freeze-dried powder and dexamethasone. Compared with the prior art, the complexing agent disclosed by the invention has the beneficial effects that the complexing agent for treating the vascular malformation is a sustained-release preparation formed by combining pingyangmycin, sapponin and a fibrin adhesive, is safe and effective in treatment of the vascular malformation, and has a better treatment effect; and particularly, the traditional Chinese medicine has a better effect on vein malformation, lymphatic vessel malformation and arteriovenous malformation.

Systems and methods treat superficial venous malformations, such as varicose or spider veins. The systems and methods distribute a reactive agent, e.g., a light-reactive agent such as talaporfin sodium or verteporfin, at or near an inner wall of a superficial feeder vein leading to the varicose or spider veins. The systems and methods activate the reactive agent by applying energy, e.g. non-thermal light energy at a wavelength that activates the reactive agent to cause localized injury to the inner wall of the superficial feeder vein to close the feeder vein to interrupt blood flow to the varicose or spider veins, which consequently shrink.